A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Eosinophils are a type of white blood cell. Elevated eosinophil levels can damage the heart, nerves, and other organs, in the syndrome known as hypereosinophilic syndrome (HES). Some individuals have a hereditary form of HES known as familial eosinophilia (FE). More research on the causation and mechanisms of HES is needed in order to design more effective and less toxic therapies. This study will investigate FE and its genetic causes, damage mechanisms, and disease markers (such as blood test abnormalities). It will enroll approximately 50 individuals (both adults and children) from a previously studied family with FE. This is a long-term study of indefinite duration. Participants will undergo yearly clinical examinations including medical history, physical examination, bloodwork, EKG, echocardiogram, and pulmonary function tests, with additional or more frequent examinations and tests as required. In addition, participants will donate blood and tissue for research purposes. Both adult and child participants will donate blood. At the initial evaluation, adult participants will donate bone marrow. During the study, some adult participants will also undergo a limited number of leukaopheresis sessions, in which blood is donated from one arm, the blood is separated into red blood cells and other components, and the red blood cells are returned into the donor's other arm.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 100
Healthy Volunteers: t
View:

⁃ In order to be eligible to participate in this study, an individual must meet all of the following criteria:

• Stated willingness to comply with all study procedures and availability for the duration of the study

• Male or female, aged 1-100 years of age

• Genetically related member of a previously identified family with FE

• Ability of subject to understand and the willingness to sign a written informed consent document.

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Thomas W Brown, R.N.
browntw@mail.nih.gov
(301) 402-7823
Backup
Amy D Klion, M.D.
aklion@niaid.nih.gov
(240) 381-6073
Time Frame
Start Date: 2005-06-08
Participants
Target number of participants: 50
Treatments
Affected family members
Family members with peripheral blood eosinophilia
Unaffected family members
Family members without peripheral blood eosinophilia
Related Therapeutic Areas
Sponsors
Leads: National Institute of Allergy and Infectious Diseases (NIAID)

This content was sourced from clinicaltrials.gov